Intrexon Corporation (NYSE:XON) major shareholder Randal J. Kirk bought 2,727,273 shares of the business’s stock in a transaction dated Monday, December 11th. The shares were bought at an average cost of $0.77 per share, for a total transaction of $2,100,000.21. The acquisition was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Intrexon Corporation (NYSE:XON) traded up $0.46 on Wednesday, reaching $13.19. The company had a trading volume of 970,871 shares, compared to its average volume of 1,136,284. Intrexon Corporation has a one year low of $10.26 and a one year high of $29.39. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85.

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC lifted its holdings in shares of Intrexon by 2,031.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after buying an additional 4,937 shares during the period. Steward Partners Investment Advisory LLC purchased a new stake in shares of Intrexon in the 3rd quarter worth $121,000. Federated Investors Inc. PA purchased a new stake in shares of Intrexon in the 2nd quarter worth $172,000. SG Americas Securities LLC purchased a new stake in shares of Intrexon in the 3rd quarter worth $139,000. Finally, Principal Financial Group Inc. purchased a new stake in shares of Intrexon in the 2nd quarter worth $212,000. Institutional investors and hedge funds own 77.49% of the company’s stock.

Several research firms have recently weighed in on XON. Northland Securities reissued a “buy” rating and set a $27.00 target price on shares of Intrexon in a research report on Friday, October 6th. BidaskClub cut Intrexon from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 22nd. JMP Securities restated an “outperform” rating and set a $42.00 price objective on shares of Intrexon in a report on Thursday, October 5th. Griffin Securities restated a “buy” rating and set a $55.00 price objective on shares of Intrexon in a report on Friday, October 6th. Finally, Bank of America dropped their price objective on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $38.50.

WARNING: “Intrexon Corporation (XON) Major Shareholder Purchases $2,100,000.21 in Stock” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/13/intrexon-corporation-xon-major-shareholder-purchases-2100000-21-in-stock.html.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Insider Buying and Selling by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.